Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals has inked an exclusive licensing agreement with Allist for two of its drugs, Glecirasib and JAB-3312, covering various regions in Greater China. The deal involves an upfront payment and R&D compensation totaling RMB200 million, with potential milestones that could add up to RMB700 million, plus tiered royalty payments for net sales. This strategic partnership is expected to boost the development and commercialization of the new treatments, with Jacobio retaining rights outside the agreed territories.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.